Navepegritide CHMP opinion moves weekly TransCon CNP toward an EU licence in achondroplasia

The navepegritide CHMP opinion brings Ascendis Pharma's weekly growth treatment close to a European licence. On 15 October 2026 the EMA's human medicines committee recommended approval of the C-type natriuretic peptide prodrug for children with achondroplasia, the most common form of dwarfism. The US cleared it in February 2026 under the brand Yuviwel. The European Commission now has the final word.

What the committee backed

According to Ascendis, the recommended use covers children aged two years and older with achondroplasia whose growth plates are still open. The drug is injected once a week. Navepegritide is built on the company's TransCon technology, which links a drug to a carrier through a cleavable chemical bridge so that the active substance is released slowly. Here the active substance is C-type natriuretic peptide, or CNP, a natural signal that promotes bone growth at the growth plate. In achondroplasia, a gain of function variant in the FGFR3 receptor puts a brake on that growth. A review in the journal Drugs explains that continuous exposure to active CNP is meant to counter the overactive receptor signalling, which in turn should increase how fast children grow.

The opinion rests on three randomized, double blind, placebo controlled trials and up to three years of open label extension data, the company said. Ascendis chief executive Jan Mikkelsen said the company was "pleased to receive this positive opinion reflecting the unique profile of TransCon CNP." The company expects the Commission decision in the fourth quarter of 2026 and plans a first European launch in Germany in the first quarter of 2027. One detail is still open. The drug carried orphan status during development, and Ascendis said the EMA will now review whether that designation can be kept. Orphan status matters because it brings market exclusivity in the EU.

Inside the ApproaCH trial

The pivotal study, ApproaCH, was published in JAMA Pediatrics. It enrolled 84 children aged 2 to 11 with genetically confirmed achondroplasia at ten hospitals in Australia, Canada, Denmark, Ireland, New Zealand, Spain and the United States. None had received growth promoting treatment before. Children were randomized two to one, with 57 receiving navepegritide and 27 receiving placebo for 52 weeks. The main measure was annualized growth velocity, the rate of height gain over a year. The drug beat placebo by 1.49 centimetres per year, with a 95 percent confidence interval of 1.05 to 1.93. Two children on the drug stopped treatment early, one at week 26 and one at week 34.

The drug beat placebo by 1.49 centimetres per year, with a 95 percent confidence interval of 1.05 to 1.93.

The paper also reports gains beyond height. Leg alignment measures improved, including the tibial femoral angle and the mechanical axis deviation, and the ratio of fibula to tibia length shifted in a favourable direction. Physical functioning scores improved in children younger than five. On safety, the authors reported no treatment related serious adverse events and no deaths, low rates of local skin reactions, and no symptomatic low blood pressure or fractures. Two correction notices covering tables and text have since appeared in the journal, which readers should check before quoting individual figures. The open label extension is still running and will supply the longer term safety record.

How navepegritide fits the market

Achondroplasia already has a CNP based treatment in Europe. BioMarin's vosoritide is a CNP analog given as a daily injection. Navepegritide's selling point is weekly dosing and continuous rather than peak and trough exposure. The trials did not compare the two drugs directly, so claims of superiority on growth would be premature. What the weekly schedule offers is fewer injections for young children, which matters to families. Ascendis is also testing whether navepegritide can be paired with its weekly growth hormone, lonapegsomatropin. In the phase 2 COACH study of 21 children, published in the European Journal of Endocrinology, the combination produced faster growth than matched children on navepegritide alone, though that comparison was not randomized.

This is a second hormone pathway product for Ascendis built on the same carrier technology. The first, palopegteriparatide for hypoparathyroidism, reached the US market after a delay that we covered when palopegteriparatide was approved in 2024. For readers who track this class, the hormone pathway molecules on our board group drugs that replace or steer a natural signal. The navepegritide CHMP opinion adds a growth signal to that list. Commercially, the size of the European opportunity will depend on pricing and reimbursement talks country by country, as with any rare disease medicine, and those talks can take a year or more in some markets.

Open questions after the opinion

The central uncertainty is what extra growth means over a lifetime. Annualized growth velocity is a surrogate measure. Whether a gain of about one and a half centimetres per year adds up to meaningful final adult height, and whether it reduces the medical complications of achondroplasia, will take years of follow up to show. That is why the US approval was accelerated rather than full, with confirmation of clinical benefit still expected. European regulators may attach similar obligations, and the final product information will show how the Commission frames them. Until those long term data exist, the benefit argument rests on growth rate, leg alignment and short term function scores.

Other questions are practical. The opinion covers children with open growth plates, so the treatment window closes at puberty, and earlier starts may matter. Families will weigh weekly injections against daily ones and against no treatment. Clinicians will also want guidance on monitoring bone age and growth plate closure during treatment. Meanwhile, the orphan status review could affect how long Ascendis keeps exclusivity. The navepegritide CHMP opinion is therefore a strong regulatory step, but the long term value case is still being built. The next checkpoint is the Commission decision later this year, followed by the outcome of the orphan review and the first national pricing talks.

Conclusion

The navepegritide CHMP opinion recommends Ascendis Pharma's weekly CNP prodrug for children with achondroplasia in Europe, backed by a randomized trial showing faster growth than placebo. A Commission decision is expected in the fourth quarter. Watch for that decision, the orphan status review and long term height data.